These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36966266)

  • 1. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
    Wang C; Sallman DA
    Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raising the bar for lower-risk myelodysplastic syndromes.
    Venugopal S; Sekeres MA
    Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
    Randall MP; DeZern AE
    Cancer J; 2023 May-Jun 01; 29(3):152-159. PubMed ID: 37195771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of lower-risk myelodysplastic syndromes].
    Ichikawa M
    Rinsho Ketsueki; 2020; 61(9):1212-1217. PubMed ID: 33162518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
    Wang C; Sallman DA
    Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes current treatment algorithm 2018.
    Steensma DP
    Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical decision-making and treatment of myelodysplastic syndromes.
    Hellström-Lindberg ES; Kröger N
    Blood; 2023 Dec; 142(26):2268-2281. PubMed ID: 37874917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: moving towards personalized management.
    Hellström-Lindberg E; Tobiasson M; Greenberg P
    Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving therapies for lower-risk myelodysplastic syndromes.
    Bewersdorf JP; Zeidan AM
    Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment for low-risk myelodysplastic syndromes].
    Morita Y
    Rinsho Ketsueki; 2018; 59(10):2050-2057. PubMed ID: 30305508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.